Control Bionics Ltd (CBL) - Total Assets
Based on the latest financial reports, Control Bionics Ltd (CBL) holds total assets worth AU$9.93 Million AUD (≈ $7.03 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Control Bionics Ltd (CBL) net asset quality to measure how much of total assets are equity-financed.
Control Bionics Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Control Bionics Ltd's total assets have evolved over time, based on quarterly financial data. Check Control Bionics Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Control Bionics Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Control Bionics Ltd's total assets of AU$9.93 Million consist of 38.5% current assets and 61.5% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 7.2% |
| Accounts Receivable | AU$1.40 Million | 17.0% |
| Inventory | AU$409.64K | 5.0% |
| Property, Plant & Equipment | AU$843.95K | 10.3% |
| Intangible Assets | AU$3.88 Million | 47.1% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Control Bionics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Control Bionics Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Control Bionics Ltd's current assets represent 38.5% of total assets in 2024, a decrease from 53.1% in 2014.
- Cash Position: Cash and equivalents constituted 7.2% of total assets in 2024, down from 36.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 6.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 47.1% of total assets.
Control Bionics Ltd Competitors by Total Assets
Key competitors of Control Bionics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Inspire Medical Systems Inc
NYSE:INSP
|
USA | $911.38 Million |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥1.59 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Stratec SE
XETRA:SBS
|
Germany | €443.38 Million |
|
Scandinavian Medical Solutions AS
CO:SMSMED
|
Denmark | Dkr205.86 Million |
|
Duearity AB
ST:DEAR
|
Sweden | Skr10.84 Million |
Control Bionics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.22 | 1.61 | 22.36 |
| Quick Ratio | 2.04 | 1.34 | 21.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$2.63 Million | AU$1.28 Million | AU$15.22 Million |
Control Bionics Ltd - Advanced Valuation Insights
This section examines the relationship between Control Bionics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.21 |
| Latest Market Cap to Assets Ratio | 3.22 |
| Asset Growth Rate (YoY) | -8.8% |
| Total Assets | AU$8.23 Million |
| Market Capitalization | $26.53 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Control Bionics Ltd's assets at a significant premium (3.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Control Bionics Ltd's assets decreased by 8.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Control Bionics Ltd (2014–2024)
The table below shows the annual total assets of Control Bionics Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$8.23 Million ≈ $5.83 Million |
-8.80% |
| 2023-12-31 | AU$9.03 Million ≈ $6.39 Million |
+3.81% |
| 2022-12-31 | AU$8.70 Million ≈ $6.15 Million |
-35.28% |
| 2021-12-31 | AU$13.44 Million ≈ $9.51 Million |
-26.79% |
| 2020-12-31 | AU$18.35 Million ≈ $12.99 Million |
-10.53% |
| 2019-12-31 | AU$20.51 Million ≈ $14.51 Million |
+277.82% |
| 2018-12-31 | AU$5.43 Million ≈ $3.84 Million |
-13.91% |
| 2017-12-31 | AU$6.31 Million ≈ $4.46 Million |
-99.46% |
| 2016-12-31 | AU$1.16 Billion ≈ $819.21 Million |
+65.93% |
| 2015-12-31 | AU$697.75 Million ≈ $493.71 Million |
+19.86% |
| 2014-12-31 | AU$582.12 Million ≈ $411.89 Million |
-- |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more